Publications by authors named "Mark A Demitrack"

Claim this Profile
O
Oliceridine for postoperative pain and opioid-related complications: The intravenous oliceridine and opioid-related complications (VOLITION) prospective cohort study.
Daniel I Sessler, Sabry Ayad, Omer Bakal, Nataya S Disher, Jorge Araujo Duran, Mark A Demitrack

J Clin Anesth· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TMS and EEG Pharmacodynamic Effects of a Selective Sphingosine-1-Phosphate Subtype 1 Receptor Agonist on Cortical Excitability in Healthy Subjects.
Catherine M K E de Cuba, Annika A de Goede, Erica S Klaassen, Marije E Otto, Robert J Doll, Mark A Demitrack

Clin Pharmacol Ther· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Multisite, 6-Month, Open-Label Study of Maintenance Transcranial Magnetic Stimulation for Adolescents with Treatment-Resistant Depression.
Juan F Garzon, Ahmed Z Elmaadawi, Scott T Aaronson, G Randolph Schrodt, Richard C Holbert, Mark A Demitrack

J Child Adolesc Psychopharmacol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Respiratory Effects of Biased Ligand Oliceridine in Older Volunteers: A Pharmacokinetic-Pharmacodynamic Comparison with Morphine.
Pieter Simons, Rutger van der Schrier, Maarten van Lemmen, Simone Jansen, Kiki W K Kuijpers, Mark A Demitrack

Anesthesiology· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neurostructural Differences in Adolescents With Treatment-Resistant Depression and Treatment Effects of Transcranial Magnetic Stimulation.
Bhedita J Seewoo, Jennifer Rodger, Mark A Demitrack, Karen L Heart, John D Port

Int J Neuropsychopharmacol· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Budget impact and pharmacy costs with targeted use of oliceridine for postsurgical pain in patients at high risk of opioid-related adverse events.
Kit N Simpson, Michael J Fossler, Linda Wase, Mark A Demitrack, Todd L Wandstrat

Expert Rev Pharmacoecon Outcomes Res· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oliceridine Exhibits Improved Tolerability Compared to Morphine at Equianalgesic Conditions: Exploratory Analysis from Two Phase 3 Randomized Placebo and Active Controlled Trials.
Gregory B Hammer, Ashish K Khanna, Cathy Michalsky, Linda Wase, Mark A Demitrack

Pain Ther· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intracellular uptake of agents that block the hERG channel can confound the assessment of QT interval prolongation and arrhythmic risk.
Alexander Burashnikov, Hector Barajas-Martinez, Robert Cox, Mark A Demitrack, Michael J Fossler

Heart Rhythm· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness and cost-benefit analysis of oliceridine in the treatment of acute pain.
Kit N Simpson, Michael J Fossler, Linda Wase, Mark A Demitrack

J Comp Eff Res· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oliceridine is Associated with Reduced Risk of Vomiting and Need for Rescue Antiemetics Compared to Morphine: Exploratory Analysis from Two Phase 3 Randomized Placebo and Active Controlled Trials.
Timothy L Beard, Cathy Michalsky, Keith A Candiotti, Paul Rider, Linda Wase, Mark A Demitrack

Pain Ther· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low Incidence of Opioid-Induced Respiratory Depression Observed with Oliceridine Regardless of Age or Body Mass Index: Exploratory Analysis from a Phase 3 Open-Label Trial in Postsurgical Pain.
Marek Brzezinski, Gregory B Hammer, Keith A Candiotti, Sergio D Bergese, Peter H Pan, Mark A Demitrack

Pain Ther· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low Incidence of Postoperative Respiratory Depression with Oliceridine Compared to Morphine: A Retrospective Chart Analysis.
Sergio Bergese, Richard Berkowitz, Paul Rider, Martin Ladouceur, Suzanne Griffith, Mark A Demitrack

Pain Res Manag· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Left prefrontal transcranial magnetic stimulation for treatment-resistant depression in adolescents: a double-blind, randomized, sham-controlled trial.
Paul E Croarkin, Ahmed Z Elmaadawi, Scott T Aaronson, G Randolph Schrodt, Richard C Holbert, Mark A Demitrack

Neuropsychopharmacology· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Benefit and Risk Evaluation of Biased μ-Receptor Agonist Oliceridine versus Morphine.
Albert Dahan, C Jan van Dam, Marieke Niesters, Monique van Velzen, Michael J Fossler, Mark A Demitrack

Anesthesiology· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating the Incidence of Opioid-Induced Respiratory Depression Associated with Oliceridine and Morphine as Measured by the Frequency and Average Cumulative Duration of Dosing Interruption in Patients Treated for Acute Postoperative Pain.
Sabry Ayad, Mark A Demitrack, David A Burt, Cathy Michalsky, Linda Wase

Clin Drug Investig· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I, Randomized, Single‑Blind, Placebo‑Controlled, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneous and Oral TRV250, a G Protein-Selective Delta Receptor Agonist, in Healthy Subjects.
Michael J Fossler, Virginia Schmith, Stephen A Greene, Lauren Lohmer, Michael S Kramer, Mark A Demitrack

CNS Drugs· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment-Resistant Depression in Adolescents: Clinical Features and Measurement of Treatment Resistance.
Jeffrey R Strawn, Scott T Aaronson, Ahmed Z Elmaadawi, G Randolph Schrodt, Richard C Holbert, Mark A Demitrack

J Child Adolesc Psychopharmacol· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
APOLLO-2: A Randomized, Placebo and Active-Controlled Phase III Study Investigating Oliceridine (TRV130), a G Protein-Biased Ligand at the μ-Opioid Receptor, for Management of Moderate to Severe Acute Pain Following Abdominoplasty.
Neil K Singla, Franck Skobieranda, David G Soergel, Monica Salamea, David A Burt, Mark A Demitrack

Pain Pract· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The assessment of resistance to antidepressant treatment: Rationale for the Antidepressant Treatment History Form: Short Form (ATHF-SF).
Harold A Sackeim, Scott T Aaronson, Mark T Bunker, Charles R Conway, Mark A Demitrack

J Psychiatr Res· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Can Medication Free, Treatment-Resistant, Depressed Patients Who Initially Respond to TMS Be Maintained Off Medications? A Prospective, 12-Month Multisite Randomized Pilot Study.
Noah S Philip, David L Dunner, Sheila M Dowd, Scott T Aaronson, David G Brock, Mark A Demitrack

Brain Stimul· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum to "Can Medication Free, Treatment-Resistant, Depressed Patients Who Initially Respond to TMS Be Maintained Off Medications? A Prospective, 12-Month Multisite Randomized Pilot Study" [Brain Stimulation 9 (2016) 251-257].
Noah S Philip, David L Dunner, Sheila M Dowd, Scott T Aaronson, David G Brock, Mark A Demitrack

Brain Stimul· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A multisite, naturalistic, observational study of transcranial magnetic stimulation for patients with pharmacoresistant major depressive disorder: durability of benefit over a 1-year follow-up period.
David L Dunner, Scott T Aaronson, Harold A Sackeim, Philip G Janicak, Linda L Carpenter, Mark A Demitrack

J Clin Psychiatry· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transcranial magnetic stimulation (TMS) for major depression: a multisite, naturalistic, observational study of quality of life outcome measures in clinical practice.
Philip G Janicak, David L Dunner, Scott T Aaronson, Linda L Carpenter, Terrence A Boyadjis, Mark A Demitrack

CNS Spectr· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Left dorsolateral prefrontal transcranial magnetic stimulation (TMS): sleep factor changes during treatment in patients with pharmacoresistant major depressive disorder.
Peter B Rosenquist, Andrew Krystal, Karen L Heart, Mark A Demitrack, W Vaughn McCall

Psychiatry Res· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transcranial magnetic stimulation (TMS) for major depression: a multisite, naturalistic, observational study of acute treatment outcomes in clinical practice.
Linda L Carpenter, Philip G Janicak, Scott T Aaronson, Terrence Boyadjis, David G Brock, Mark A Demitrack

Depress Anxiety· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis